lomustine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 96 Diseases   29 Trials   29 Trials   1185 News 


«12...45678910111213141516»
  • ||||||||||  cyclophosphamide intravenous / Generic Mfg.
    Adult medulloblastoma treatment impact since 2006: a Canadian University center experience (Ballroom Lawn) -  Oct 29, 2019 - Abstract #SNO2019SNO_1106;    
    78% of the progressive patients received second line chemo. CONCLUSION In our adult MB population, the demographic and tumor factors did’nt have an impact on prognosis but adjuvant radiotherapy and chemotherapy had a favorable impact on survival especially with Cisplatin, Etoposide and Cyclophosphamide regimen.
  • ||||||||||  Avastin (bevacizumab) / Roche
    A Unique Case of Primary Gliosarcoma with Metastasis to Sacrum on Bevacizumab (Ballroom Lawn) -  Oct 29, 2019 - Abstract #SNO2019SNO_992;    
    To the best of our knowledge, this is the first case primary of gliosarcoma with metastases to the sacrum while evolved on chemotherapy with bevacizumab. The aim of this report is to bring awareness to medical community in order to expedite the diagnosis and management.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Feasibility study of the EMulate Therapeutics™ Voyager system in patients with recurrent glioblastoma (GBM) (Ballroom Lawn) -  Oct 29, 2019 - Abstract #SNO2019SNO_951;    
    The aim of this report is to bring awareness to medical community in order to expedite the diagnosis and management.  The Voyager system appears to be safe and feasible for the treatment of recurrent GBM.  Given that therapy is delivered non-invasively and no device-related serious adverse events were reported, further prospective study of the investigational device is planned.
  • ||||||||||  temozolomide / Generic Mfg.
    Adjuvant chemotherapy after severe myelotoxicity during temozolomide chemoradiation in gliomas. It is feasibile? (Ballroom Lawn) -  Oct 29, 2019 - Abstract #SNO2019SNO_505;    
    Among patients treated with TMZ, 13 patients presented hematological toxicity grade 3–4 which required treatment discontinuation in 7 cases (20%). CONCLUSION the results of our study show that 80% of glioma patients presenting severe myelotoxicity during concomitant radiochemotherapy may be treated with maintenance TMZ after recovery of myelosuppression.
  • ||||||||||  vocimagene amiretrorepvec (Toca 511) / Tocagen, Avastin (bevacizumab) / Roche
    Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (Grand Canyon Ballroom) -  Oct 29, 2019 - Abstract #SNO2019SNO_180;    
    P2/3
    Three Ph1 studies in patients with recurrent high grade glioma have demonstrated a tolerable safety profile and encouraging efficacy.METHODS Toca 5 is a multi-national, randomized, open-label Ph3 trial (NCT02414165) of Toca 511 & Toca FC versus standard of care (SOC) options that comprises Investigator’s choice of single agent chemotherapy (lomustine, temozolomide) or bevacizumab in patients who have undergone resection for first or second recurrence of glioblastoma or anaplastic astrocytoma...Pre-planned subgroup analyses showed compelling OS improvement in patients with secondary recurrence, and favorable trends in IDH1 mutant and AA population. Detailed data will be presented at the time of the conference.
  • ||||||||||  Chronic Interstitial Nephritis in Agricultural Communities (CINAC): A Toxin-Induced Proximal Lysosomal Tubulopathy (Salon A/B, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_5020;    
    Rats treated with cyclosporine for 4 weeks developed similar PTC lysosomal alterations, that were absent in a dehydration group. Conclusion A sensitive constellation of renal PTC lesions was detected associated with CINAC and CNI nephrotoxicity in several countries, suggesting a common new paradigm where CINAC patients are experiencing a tubulotoxic mechanism similar to CNI nephrotoxicity, the latter also being known as a direct or indirect effect of pesticides.
  • ||||||||||  melphalan / Generic Mfg., Cytoxan oral (cyclophosphamide oral) / Generic Mfg., etoposide IV / Generic Mfg.
    Retrospective data, Journal:  LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. (Pubmed Central) -  Sep 27, 2019   
    BEAM (BCNU/carmustine, etoposide, cytarabine, and melphalan) is the most commonly used conditioning regimen for ASCT in patients with relapsed/refractory (R/R) lymphomas in Europe, whereas the CBV (cyclophosphamide, BCNU, and etoposide) regimen is also widely used in North America...Thus, in the current manuscript, we report the experience of 2 transplant centers in ASCT in R/R lymphomas with three types of conditioning: BEAM, CLV (cyclophosphamide, lomustine, etoposide) and LEAM (lomustine, etoposide, cytarabine, and melphalan), with the aim to evaluate the results of alternative conditioning regimens using lomustine (LEAM and CLV) and compare them with the standard BEAM regarding early toxicity, engraftment, and transplant related mortality (TRM)...For the BEAM arm, one patient developed grade 3 cardiac toxicity with sinus bradycardia and afterwards grade 4 with acute pulmonary edema, three patients presented a grade 3 pruritic skin rash and two patients developed grade 3 seizures. In the present study we presented the differences that were observed between BEAM, LEAM, and CLV conditioning regimens offering clinical arguments for an SCT practitioner choice in the ideal situation, but also of choice for alternative regimens in the case that one regimen cannot be used.
  • ||||||||||  elraglusib (9-ING-41) / Actuate Therap
    Enrollment change, Metastases:  Actuate 1801: 9-ING-41 in Patients with Advanced Cancers (clinicaltrials.gov) -  Sep 23, 2019   
    P1/2,  N=350, Recruiting, 
    Because ATRi's are known radiosensitizers, we believe that novel combinations of ATRi’s, lomustine, and re-RT may have promise in recurrent GBM. N=250 --> 350
  • ||||||||||  lomustine / generics, vincristine / generics
    Tolerability of PCV in low grade glioma: A real world experience (Poster Area (Hall 4)) -  Sep 11, 2019 - Abstract #ESMO2019ESMO_1560;    
    Our data suggest it might be preferable to adjust doses from the start of chemotherapy to improve tolerability. Legal entity responsible for the study: The authors.
  • ||||||||||  galunisertib (LY2157299) / Eli Lilly
    Trial completion date, Combination therapy, Monotherapy:  A Dose-Escalation Study in Participants With Recurrent Malignant Glioma (clinicaltrials.gov) -  Sep 4, 2019   
    P1,  N=66, Active, not recruiting, 
    No abstract available Trial completion date: Aug 2019 --> Dec 2019
  • ||||||||||  lomustine / generics, temozolomide / generics, vincristine / generics
    Journal:  Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network. (Pubmed Central) -  Aug 7, 2019   
    The heterogeneity in the management of patients with DLGG demonstrates that many questions regarding the postoperative strategy and the use of chemotherapy remain unanswered. Our survey reveals a high recruitment potential within the ELGGN for retrospective or prospective studies to generate new data regarding these issues.
  • ||||||||||  depatuxizumab (ABT-806) / AbbVie, Life Science Pharma, Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal:  How we treat glioblastoma. (Pubmed Central) -  Jul 13, 2019   
    Immunotherapy remains experimental. Drugs in advanced clinical development include the programmed death 1 antibody, nivolumab, the antibody drug conjugate depatuxizumab directed to the epidermal growth factor receptor and the proteasome inhibitor marizomib.
  • ||||||||||  lomustine / generics, temozolomide / generics
    Journal:  Lomustine-temozolomide combination efficacious in newly diagnosed glioblastoma. (Pubmed Central) -  Jul 11, 2019   
    Drugs in advanced clinical development include the programmed death 1 antibody, nivolumab, the antibody drug conjugate depatuxizumab directed to the epidermal growth factor receptor and the proteasome inhibitor marizomib. No abstract available
  • ||||||||||  lomustine / generics, temozolomide / generics, vincristine / generics
    Journal:  The Role of Chemotherapy in the Treatment of Low-grade Gliomas (Pubmed Central) -  Jul 1, 2019   
    ...The long-term results of a RTOG 9802 comparing radiotherapy alone with radiotherapy and six cycles of adjuvant PCV chemotherapy (procarbazine, lomustine, vincristine) in patients with high-risk low-grade gliomas will probably have an impact on daily clinical practice...It is still unclear whether less toxic temozolomide can replace PCV and whether temozolomide can be used upfront alone instead of with radiotherapy...3. 2017.
  • ||||||||||  lomustine / generics
    Journal, Oncolytic Virus:  Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells. (Pubmed Central) -  Jun 19, 2019   
    ...Lomustine is generally accepted as the first-line systemic therapy, although this compound does not provide complete regression...Additionally, we demonstrated that susceptibility to reovirus-induced cell death was attributable to the extent of expression of type I interferons induced by reovirus infection in vitro. In conclusion, oncolytic reovirus appears to be an effective treatment option for histiocytic sarcoma, and therefore warrants further investigation in early clinical trials.
  • ||||||||||  galunisertib (LY2157299) / Eli Lilly
    Trial completion date, Combination therapy, Monotherapy:  A Dose-Escalation Study in Participants With Recurrent Malignant Glioma (clinicaltrials.gov) -  Jun 5, 2019   
    P1,  N=66, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Feb 2020 --> Jun 2019 | Trial primary completion date: Feb 2020 --> Jun 2019 Trial completion date: May 2019 --> Aug 2019
  • ||||||||||  lomustine / generics, carmustine / generics
    Journal:  Carnosic Acid Impedes Cell Growth and Enhances Anti-cancer Effects of Carmustine and Lomustine in Melanoma. (Pubmed Central) -  Apr 17, 2019   
    Additionally, CA can enhance BCNU- and CCNU-mediated cytotoxicity and cell cycle arrest in B16F10 cells. Finally, we find that CA inhibits tumor growth, and reduces the values of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in vivo This study concludes that CA may be safe and useful as a novel chemotherapeutic agent.
  • ||||||||||  disulfiram / Generic mfg.
    Trial completion date, Trial primary completion date:  Disulfiram in Recurrent Glioblastoma (clinicaltrials.gov) -  Apr 4, 2019   
    P2/3,  N=142, Recruiting, 
    To establish a robust guideline for LGG, further studies including molecular information are needed. Trial completion date: Sep 2020 --> Sep 2023 | Trial primary completion date: Dec 2019 --> Dec 2021
  • ||||||||||  lomustine / Generic mfg., cisplatin / Generic mfg., vincristine / Generic mfg.
    Trial completion date, Trial primary completion date, Surgery:  Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma (clinicaltrials.gov) -  Feb 27, 2019   
    P=N/A,  N=6, Active, not recruiting, 
    Trial completion date: Aug 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020 Trial completion date: Feb 2019 --> Feb 2020 | Trial primary completion date: Feb 2019 --> Feb 2020